Compare GPK & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GPK | HCM |
|---|---|---|
| Founded | 2007 | 2000 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.3B |
| IPO Year | 2007 | 2015 |
| Metric | GPK | HCM |
|---|---|---|
| Price | $10.87 | $14.83 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 11 |
| Target Price | $12.10 | ★ $21.14 |
| AVG Volume (30 Days) | ★ 8.1M | 39.3K |
| Earning Date | 11-03-2026 | 07-30-2026 |
| Dividend Yield | ★ 4.08% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $8,617,000,000.00 | N/A |
| Revenue This Year | $0.33 | $14.11 |
| Revenue Next Year | $1.91 | $11.97 |
| P/E Ratio | $1,079.50 | ★ $5.49 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.15 | $9.77 |
| 52 Week High | $16.61 | $16.33 |
| Indicator | GPK | HCM |
|---|---|---|
| Relative Strength Index (RSI) | 61.67 | 58.76 |
| Support Level | $10.09 | $13.00 |
| Resistance Level | $11.31 | $15.55 |
| Average True Range (ATR) | 0.46 | 0.39 |
| MACD | 0.13 | 0.12 |
| Stochastic Oscillator | 67.39 | 78.46 |
Graphic Packaging Holding Co is a holding company that manufactures and sells a variety of paper-based consumer packaging products through its subsidiaries. The company's reportable segments are; Americas Paperboard Packaging, and International Paperboard Packaging. The majority of the revenue is generated from its Americas Paperboard Packaging segment which includes paperboard packaging sold predominantly to consumer packaged goods (CPG) companies and cups, lids and food containers sold to foodservice companies and quick-service restaurants (QSR) serving the food, beverage, and consumer product markets in the Americas. Geographically, the company operates in Americas, Europe and Asia Pacific regions.
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.